This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a view of the thyroid cancer market not available elsewhere. This reports gives an overview of the current and future thyroid cancer clinical development market, the activities of the key market players, and outlines trial and commercial regulatory environments. Learn more: http://www.isrreports.com/product/thyroid-cancer-disease-pipeline-analysis/

1. Thyroid Cancer
Thyroid Cancer:
Disease and Pipeline
Analysis
Info@ISRreports.com
©2014 Industry Standard Research www.ISRreports.com
PREVIEW

2. Major Sections:
1. Disease Overview
2. Epidemiology
3. Diagnosis and Staging
4. Tumour Classification
5. Treatment of Thyroid Cancer
6. Thyroid Cancer Prognosis
7. Environmental Analysis
8. Drug Development in Thyroid Cancer
What you will learn in this report:
• Global and country-specific incidence rates for thyroid cancer
• Active development pipeline, including promising new therapies currently in Early and Late
• Analysis of clinical trial environments for new thyroid cancer therapies
• Areas of unmet need
How you can use this report:
• Identify and enhance commercial and development opportunities with an in-depth and
current analysis of the global thyroid cancer market
• Understand how products currently in development could impact this market
• Assess the competition with an analysis and summary of companies active in this space
www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 2
act with confidence
Report Overview
This report offers a unique therapeutic assessment and in-depth market and pipeline analysis, providing a
view of the thyroid cancer market not available elsewhere. This reports gives an overview of the current and
future thyroid cancer clinical development market, the activities of the key market players, and outlines trial
and commercial regulatory environments.
6.4%
Average annual increase
in thryroid cancer
incidence in the U.S.
27
Charts and Graphs
91
Pages
Phases of development
Valuable for:
• Brand Managers
• Portfolio Managers
• Research & Development
• Managed Markets
NEXT: Table of contents and sample pages

3. www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 3
act with confidence
Table of Contents
For full table of contents and additional sample pages, download the full preview
from ISR’s website: www.isrreports.com

4. Table 1. Incidence of Thyroid Cancer in the Major Markets
Table 2. Incidence of Thyroid Cancer in Emerging Markets
Table 3. Age at Diagnosis of Thyroid Cancer (US)
Table 4. Incidence Rate of Thyroid Cancer by Ethnicity (US)
Table 5. Thyroid Cancer Mortality in the Major Markets
Table 6. Age at Death from Thyroid Cancer (US)
Table 7. Classification of Primary Tumour, Lymph Nodes and Metastases in Thyroid Cancer
Table 8. Staging for Differentiated Thyroid Cancer in Patients >45 Years and Medullary
Thyroid Cancer in Patients of All Ages
Table 9. Staging for Anaplastic Thyroid Cancer
Table 10. Summary of ATA and ETA Tumour Recurrence Risk Stratification
Table 11. 5-Year Relative Survival Based on Stage at Diagnosis
Table 12. Thyroid Cancer - Major Markets Patient Population and Product Environment
Table 13. Thyroid Cancer - Emerging Markets Patient Population and Product Environment
Table 14. Number of Patients in Thyroid Cancer Clinical Trials by Phase
Table 15. Number of Patients in Pharma Sponsored Thyroid Cancer Clinical Trials by Phase
Table 16. Thyroid Cancer Development Pipeline
www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 4
act with confidence
List of Tables
List of Figures
Figure 1. Thyroid Gland
Figure 2. Global Incidence of Thyroid Cancer, Both Sexes
Figure 3. Countries with the Highest Number of Thyroid Cancer Cases (2012), Both Sexes
Figure 4. Countries with the Highest Number of Annual Deaths from Thyroid Cancer
Figure 5. Geographic Distribution of Open Thyroid Cancer Clinical Trials
Figure 6. Distribution of Industry Sponsored, Open Thyroid Cancer Trials
Figure 7. Distribution of Active Thyroid Cancer Trials, by Phase
Figure 8. Distribution of Active Pharma Industry Sponsored Thyroid Cancer Trials, by Phase
Figure 9. Major intracellular pathways targeted for the treatment of thyroid cancer

5. Thyroid Cancer Incidence
The latest figures from the World Health Organization [1] show that thyroid cancer has
a worldwide incidence of just over 298,000 diagnosed cases per year, constituting
2.1% of all cancer incidences. There is a strong gender bias to this figure with 77% of
thyroid cancer cases globally being diagnosed in women. As such, thyroid cancer is
the 8th most commonly diagnosed cancer in women, accounting for 3.5% of cancer
diagnoses, but does not feature in the 15 most common cancers for both sexes
combined.
Figure 2. Global Incidence of Thyroid Cancer, Both Sexes
The incidence of thyroid cancer is reported to be rising in many countries and regions.
In the US, the incidence of thyroid cancer has been increasing at an average rate of
6.4% each year for the past ten years [Surveillance, Epidemiology, and End Results
Registry (SEER)]. Many experts believe this increase is largely a consequence of
increased diagnosis of small, papillary tumours, identified using ultrasound techniques
and as part of diagnostic work up for other conditions. However, others point to
increasing incidence rates of thyroid cancer in countries such as India, where imaging
is not prevalent, as evidence to suggest there are other factors responsible for the
increasing incidence.
In the major pharmaceutical markets, the US has a significantly higher age standardised
rate of thyroid cancer (ASR 13.2) compared to most other countries. This is particularly
evident in the age standardised rate among women (ASR 20.0). While Italy has the next
highest total age standardised rate (ASR 10.8), the rate for men is comparable to that of
the US (ASR 6.7 and ASR 6.4 respectively), but the rate among women is much lower
www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 5
act with confidence
act with confidence
Chapter 2 - Thyroid Cancer Epidemiology
www.ISRreports.com ©2014 | Thyroid Cancer: Disease and Pipeline Analysis 17
Sample Page

6. Thyroid
Cancer
is the most rapidly increasing cancer in the U.S.
with 62,980 new cases predicted in 2014.
Thyroid cancer forms
in the thyroid gland,
a butterfly shaped
gland in the front part
of the neck.
There are often physical
signs of thyroid cancer
present such as lumps,
swelling, or nodules.
Risk Factors
Nearly 2/3 cases of thyroid
cancer are found in people
younger than 55 years of age.
Five year
survival rate:
% of thyroid cancer cases
40+
Types of thyroid cancer
radioactive iodine treatment surgery
chemotherapy
thyroid hormone therapy
External Beam
Radiation
targeted therapy
Sources: ISR reports, cancer.org, seer.cancer.gov
www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 6
act with confidence
act with confidence
Chapter 1 – Thyroid Cancer Disease Overview
www.ISRreports.com ©2014 | Thyroid Cancer: Disease and Pipeline Analysis 15
Treatment
97.8%
Women are three times more likely
to develop thyroid cancer than men.
radiation
diet low in iodine
hereditary conditions
family history
gender and age
75-85%
10-15%
3%
1-6%
5%
1-2%
Papillary
Follicular
Hürthle cell carcinoma
Poorly Dierentiated
Thyroid Carcinoma
Medullary
Anaplastic
© Industry Standard Research
Sample Page

7. www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 7
act with confidence
Sample Page
For full table of contents and additional sample pages, download the full preview
from ISR’s website: www.isrreports.com

8. For pricing and ordering information, please visit ISR’s website:
www.isrreports.com
Save on this,
or any ISR
report, by
creating a free
account
Register now
• Receive a $250 instant credit towards any ISR report
• Earn 10% credit towards all future purchases
• Receive advanced notifications on ISR’s latest reports and free resources
About Industry Standard Research
www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 8
act with confidence
Ordering Information
Industry Standard Research (ISR) is the premier, full service market research provider to the pharma and pharma services
industries. With over a decade of experience in the industry, ISR delivers an unmatched level of domain expertise.
For more information about our off-the-shelf intelligence and custom research offerings, please visit our Web site at
www.ISRreports.com, email info@ISRreports.com, or follow us on twitter @ISRreports.

9. The ISR Difference
Custom-quality syndicated market research
www.ISRreports.com
vs. Syndicated Report
ISR's Reports The Common
How confident are you?
Research methods
Data Collection
vs.
Respondents
Sample Sizes
Analysts
www.ISRreports.com ©2014 | Preview of: Thyroid Cancer: Disease and Pipeline Analysis 9
act with confidence
www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions www.ISRreports.com ©2014 | Preview of: Benchmarking European Investigator Payments 10
www.ISRreports.com ©2013 | Preview of: Benchmarking the Pharma Industry’s HEOR Functions ISR's proprietary data collection
tools and channels support fast,
high quality data collection
Struggle to recruit the right
targets and enough of them
vs.
Robust sample sizes that
instill confidence
Often insufficient industry
representation that leaves you
defending results
vvss..
Mostly primary
research;
always appropriate
for the topic
One size fits all;
usually publically
available data
vvss..
Sophisticated screening
ensures genuine
decision-makers
Undisclosed
methodologies and
respondent demographics
vvss..
Decades of experience
means more insights that are
immediately usable
Junior analysts capable of
reporting numbers